Additional information regarding these results and other relevant information is included in the notes to the financial ...

By establishing clear policies for data ownership, access and quality, you can reduce regulatory risk, improve operational ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

Hong Kong-based biopharma company Akeso (HKEX: 9926) announced that its global first-in-class PD-1/VEGF bispecific antibody, ...

US-based biotechnology company Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an independent data monitoring committee. The feedback ...

A good update was also provided here a few months ago, whereby the independent data monitoring committee (IDMC) already recommended dosing of the second cohort of this study. As I stated in the ...

The policy mandates the formation of a State Data Steering Committee (SDSC), which will coordinate and monitor the implementation of this policy in close collaboration with all departments and ...

An independent data monitoring committee (iDMC) that regularly reviews all of the data from the trial recently held their scheduled meeting and made a recommendation to modify the trial design. To cut ...